The Ludwig Institute For Cancer Research (LICR) and Pro-Pharmaceuticals, Inc. Collaborate to Test DAVANAT(R)'s Ability to Enhance the Function of Anti-Tumor T Lymphocytes

Published: Dec 15, 2009

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC:PRWP) today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

Back to news